Atyr PHARMA (NASDAQ:ATYR) Now Covered by Cantor Fitzgerald

Investment analysts at Cantor Fitzgerald assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR - Get Free Report) in a note issued to investors on Monday, Marketbeat.com reports. The brokerage set an "overweight" rating on the stock.

A number of other equities analysts have also commented on ATYR. Wells Fargo & Company assumed coverage on shares of Atyr PHARMA in a research report on Friday, October 4th. They issued an "overweight" rating and a $17.00 price target on the stock. HC Wainwright reissued a "buy" rating and issued a $35.00 target price on shares of Atyr PHARMA in a report on Tuesday, December 10th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Atyr PHARMA presently has an average rating of "Buy" and an average price target of $19.25.

Atyr PHARMA Stock Performance

Shares of ATYR stock traded down $0.01 during trading hours on Monday, hitting $3.97. The company had a trading volume of 1,358,627 shares, compared to its average volume of 1,292,576. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The company has a market cap of $333.25 million, a price-to-earnings ratio of -4.22 and a beta of 1.08. Atyr PHARMA has a 12 month low of $1.39 and a 12 month high of $4.23. The stock's fifty day moving average is $3.30.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). On average, sell-side analysts expect that Atyr PHARMA will post -0.89 EPS for the current fiscal year.

Hedge Funds Weigh In On Atyr PHARMA

An institutional investor recently raised its position in Atyr PHARMA stock. JPMorgan Chase & Co. increased its stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) by 52.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,440 shares of the company's stock after purchasing an additional 10,754 shares during the period. JPMorgan Chase & Co.'s holdings in Atyr PHARMA were worth $55,000 as of its most recent SEC filing. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.